Correction to "Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer"
- PMID: 40802348
- DOI: 10.1021/acs.molpharmaceut.5c01102
Correction to "Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer"
Erratum for
-
Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer.Mol Pharm. 2024 Nov 4;21(11):5749-5760. doi: 10.1021/acs.molpharmaceut.4c00743. Epub 2024 Oct 10. Mol Pharm. 2024. PMID: 39388218
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
